| scholarly article | Q13442814 |
| P2093 | author name string | J Silva | |
| H G Deery | |||
| R Fekety | |||
| C Kauffman | |||
| B Buggy | |||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Clostridium difficile | Q310543 |
| vancomycin | Q424027 | ||
| Clostridioides difficile colitis | Q574905 | ||
| P304 | page(s) | 15-19 | |
| P577 | publication date | 1989-01-01 | |
| P1433 | published in | American Journal of Medicine | Q2842959 |
| P1476 | title | Treatment of antibiotic-associated Clostridium difficile colitis with oral vancomycin: comparison of two dosage regimens | |
| P478 | volume | 86 |
| Q37406225 | A Prospective Pilot Study on the Systemic Absorption of Oral Vancomycin in Children With Colitis |
| Q36792749 | A new formulation of tolevamer, a novel nonantibiotic polymer, is safe and well-tolerated in healthy volunteers: a randomized phase I trial |
| Q64080527 | An Updated Review of Clostridium difficile Treatment in Pediatrics |
| Q35031203 | An agent-based simulation model for Clostridium difficile infection control |
| Q37246390 | An elderly woman with 'Red Man Syndrome' in association with oral vancomycin therapy: a case report |
| Q24234378 | Antibiotic treatment for Clostridium difficile -associated diarrhea in adults |
| Q24244302 | Antibiotic treatment for Clostridium difficile-associated diarrhea in adults |
| Q24244843 | Antibiotic treatment for Clostridium difficile-associated diarrhea in adults |
| Q30235446 | Antibiotic treatment for Clostridium difficile-associated diarrhoea in adults |
| Q37351583 | Avoiding pitfalls: what an endoscopist should know in liver transplantation--part II. |
| Q36624688 | Case-control analysis of clostridium difficile-associated diarrhea on a gynecologic oncology service |
| Q56225357 | Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA) |
| Q38445227 | Clostridium Difficile Infection from a Surgical Perspective. |
| Q74592566 | Clostridium difficile |
| Q37419825 | Clostridium difficile 30 years on: what has, or has not, changed and why? |
| Q38558966 | Clostridium difficile Diarrhea in the Elderly: Current Issues and Management Options |
| Q34234668 | Clostridium difficile infection in the inflammatory bowel disease patient. |
| Q37662628 | Clostridium difficile infection in the intensive care unit |
| Q40652823 | Clostridium difficile infection: a common clinical problem for the general internist |
| Q37176641 | Clostridium difficile infection: a critical overview |
| Q35372397 | Clostridium difficile infection: current, forgotten and emerging treatment options |
| Q37814046 | Clostridium difficile infection: epidemiology, risk factors and management |
| Q30244040 | Clostridium difficile infections in geriatric patients |
| Q42272356 | Clostridium difficile infections in solid organ transplantation |
| Q35983360 | Clostridium difficile-associated colitis |
| Q35828291 | Clostridium difficile-associated diarrhea in adults |
| Q34767730 | Clostridium difficile-associated diarrhea: current strategies for diagnosis and therapy |
| Q36407202 | Clostridium difficile-associated disease: an emerging threat to patient safety: insights from the Society of Infectious Diseases Pharmacists |
| Q36757577 | Clostridium difficile-associated disease: changing epidemiology and implications for management |
| Q36871148 | Clostridium difficile: The evolving story |
| Q26827693 | Clostridium difficile: epidemiology, diagnostic and therapeutic possibilities-a systematic review |
| Q35161614 | Comparison of planktonic and biofilm-associated communities of Clostridium difficile and indigenous gut microbiota in a triple-stage chemostat gut model |
| Q48522020 | Diagnosis and Treatment of Clostridium difficile Infection (CDI). |
| Q38334278 | Diagnosis and treatment of Clostridium difficile in adults: a systematic review. |
| Q40492948 | Drug therapy in diarrheal diseases in oncology/hematology patients |
| Q41564213 | Drug-induced Clostridium difficile-associated disease |
| Q90460848 | Effective Dosage of Oral Vancomycin in Treatment for Initial Episode of Clostridioides difficile Infection: A Systematic Review and Meta-Analysis |
| Q35164536 | Efficacy of fidaxomicin versus vancomycin as therapy for Clostridium difficile infection in individuals taking concomitant antibiotics for other concurrent infections |
| Q37014160 | Epidemiology, Diagnosis, and Management of Clostridium difficile Infection in Patients with Inflammatory Bowel Disease |
| Q44897788 | Evaluation of NVB302 versus vancomycin activity in an in vitro human gut model of Clostridium difficile infection |
| Q33782277 | Faecal pharmacokinetics of orally administered vancomycin in patients with suspected Clostridium difficile infection. |
| Q34611463 | Faecal transplant for recurrent Clostridium difficile-associated diarrhoea: a UK case series |
| Q35175136 | Future novel therapeutic agents for Clostridium difficile infection |
| Q37798821 | Impact ofClostridium difficileon inflammatory bowel disease |
| Q36753200 | In vitro synergy studies with Clostridium difficile |
| Q90086577 | Indian Antimicrobial Prescription Guidelines in Critically Ill Immunocompromised Patients |
| Q51084446 | Leaping Forward in the Treatment of Clostridium Difficile Infection: Update in 2015. |
| Q34002040 | Local and systemic neutralizing antibody responses induced by intranasal immunization with the nontoxic binding domain of toxin A from Clostridium difficile |
| Q30307170 | Management and Prevention of Clostridium difficile-Associated Diarrhea |
| Q42778196 | Managing antibiotic associated diarrhoea |
| Q37133382 | Oral Vancomycin-Induced Rash: Case Report and Review of the Literature |
| Q90890042 | Prevention and Treatment of Clostridium difficile Enterocolitis |
| Q26796548 | Rational Therapy of Clostridium difficile Infections |
| Q38470940 | Refractory pseudomembranous colitis that was treated successfully with colonoscopic fecal microbial transplantation |
| Q39175350 | Rethinking Strategies to Select Antibiotic Therapy in Clostridium difficile infection |
| Q40840258 | Review article: the use of biotherapeutic agents in the prevention and treatment of gastrointestinal disease |
| Q41479166 | Risk factors for systemic vancomycin exposure following administration of oral vancomycin for the treatment of Clostridium difficile infection |
| Q39469856 | Selective growth inhibitory effect of biochanin A against intestinal tract colonizing bacteria. |
| Q40889458 | The Addition of Intravenous Metronidazole to Oral Vancomycin is Associated With Improved Mortality in Critically Ill Patients With Clostridium difficile Infection |
| Q37421057 | The clinical significance of antibiotic-associated pseudomembranous colitis in the 1990s |
| Q41875708 | Therapeutic Success of Rifaximin for Clostridium difficile Infection Refractory to Metronidazole and Vancomycin |
| Q40110130 | Therapy for Clostridium difficile infection - any news beyond Metronidazole and Vancomycin? |
| Q37676416 | Therapy for acute infectious diarrhea in children |
| Q38139991 | Therapy of Clostridium difficile infection: perspectives on a changing paradigm |
| Q34321534 | Treatment of Clostridium difficile Infection |
| Q51894323 | Treatment of Clostridium difficile infection. |
| Q34979678 | Treatment of Clostridium difficile-associated diarrhea |
| Q36240849 | Treatment of Clostridium difficile-associated disease: old therapies and new strategies |
| Q45743162 | Treatment of pediatric Clostridium difficile infection: a review on treatment efficacy and economic value |
| Q38762168 | Update on pseudomembranous colitis |
| Q68047129 | Vancomycin |
| Q72336044 | Vancomycin |
Search more.